Tandem nRGD Polypeptide for Multi-Target Tumor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tumor-targeting therapies face limitations in effectively targeting tumor-associated macrophages and regulating the tumor microenvironment, leading to suboptimal antitumor efficacy and potential recurrence due to immune evasion and microenvironment support for tumor growth.
Innovation Solution
A novel tandem polypeptide nRGD is created by covalently linking an alanine-alanine-asparagine (AAN) sequence to an RGD-containing peptide, which targets tumor cells, vessels, and associated macrophages, enhancing antitumor effects by modifying drug delivery vectors or drugs to improve distribution and reduce toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If RGD-containing peptide is used to target tumor cells and vessels, then tumor targeting capability is improved, but tumor-associated macrophages cannot be targeted and tumor microenvironment cannot be regulated
Solution Approach 1:
The patent combines RGD peptide sequence (targets tumor cells and vessels via integrin binding) with AAN-containing sequence (targets tumor-associated macrophages via legumain recognition) into a single tandem polypeptide nRGD. This merging of two distinct targeting moieties enables simultaneous targeting of multiple tumor components including cancer cells, blood vessels, and immunosuppressive macrophages, thereby resolving the limitation of single-target RGD peptides.
Solution Approach 2:
The tandem polypeptide nRGD is designed to perform multiple functions: (1) targeting tumor cells through RGD-integrin interaction, (2) targeting tumor-associated macrophages through AAN-legumain interaction, and (3) regulating tumor microenvironment by modulating macrophage polarization. This multi-functional design allows a single agent to address multiple aspects of tumor pathology that previously required separate therapies.
2Quantity of substance
If conventional tumor-targeting therapy is used, then drug delivery to tumor cells is improved, but tumor microenvironment regulation and immune response modulation are insufficient
Solution Approach 1:
The AAN-containing sequence acts as an intermediary that specifically recognizes legumain, a protease overexpressed in tumor-associated macrophages. This intermediary element enables the polypeptide to selectively engage and modulate macrophage function, thereby regulating the tumor microenvironment and enhancing immune responses against tumor cells, which complements the direct cytotoxic effect of drug delivery to tumor cells.
3Measurement precision
If single-function targeting peptide is used, then specific target recognition is improved, but comprehensive anti-tumor effect is limited
Solution Approach 1:
The tandem polypeptide nRGD functions as a composite biomaterial that integrates two distinct peptide sequences with complementary targeting specificities. The RGD moiety provides precise binding to integrins on tumor cells and vascular endothelium, while the AAN moiety provides precise binding to legumain in tumor-associated macrophages. This composite structure maintains the high specificity of individual components while achieving synergistic anti-tumor efficacy through multi-target engagement.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nRGD polypeptide significantly enhances antitumor effects by increasing drug accumulation at tumor sites, reducing toxicity, and altering the tumor microenvironment, leading to improved survival rates and complete tumor remission in mouse models, with enhanced targeting and biotherapeutic effects.
Implementation Method 1
Studies have confirmed that tripeptide sequence containing arginine-glycine-aspartic acid (RGD) can specifically recognize and bind integrins
Implementation Method 2
The AAN-containing sequence is preferably susceptible to legumain
Data Source
AI summary
Provided is a nRGD polypeptide formed by connecting alanine-alanine-asparagine (AAN) and a polypeptide containing arginine-glycine-aspartic acid (RGD), wherein the nRGD polypeptide can target tumor vessels, tumor cells and tumor-associated macrophages, and mediate the targeted delivery of tumors.